Information  X 
Enter a valid email address

Oxurion NV (0G99)


Friday 11 September, 2020

Oxurion NV

Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September

Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September

Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September

O xurion to Host Conference Call following the H1 Financial Results        

Leuven, Belgium, 11 September 2020 – 08.15 A.M. CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies, with a focus on diabetic macular edema (DME), announces that the Company will issue its Business Update and First Half Financial Results on Thursday, September 17, 2020 at 5.45 p.m. CET.

Following the announcement, Oxurion’s management will host a conference call in English on Thursday, September 17 at 6.30 p.m. CET to discuss the Business Update, its Financial Results and to provide an overview of the progress and potential of the Company’s emerging DME Franchise.

Oxurion’s First Half 2020 Conference Call & Webcast Details:

Date: Thursday, September 17, 2020
Time: 6.30 p.m. CET / 5.30 p.m. BST

Participant telephone numbers:

Brussels: +32 (0) 2 789 8603
Belgium Toll Free: 0800 746 68
Standard International Access: +44 (0) 20 3003 2666
UK Toll Free: 0808 109 0700
USA Toll Free: 1 866 966 5335    

Password: Oxurion

There will be a live listen-only webcast of the event, accessible from the Oxurion website.

An on-demand version of the event will also be made available shortly after the event has finished.


For further information please contact:

Oxurion NV
Wouter Piepers,
Global Head of Investor Relations
& Corporate Communications
Tel: +32 16 75 13 10 / +32 478 33 56 32
[email protected]
Citigate Dewe Rogerson
David Dible/ Sylvie Berrebi/Frazer Hall
Tel: +44 20 7638 9571
[email protected]

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation, standard of care therapies to better preserve vision in patients with diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide.

Oxurion is building a leading global franchise in the treatment of DME, based on the successful development of its two novel therapeutics:

  •   THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for DME patients who respond sub-optimally to anti-VEGF therapy.

THR-149 has shown positive topline Phase 1 results for the treatment of DME.  The Company is currently conducting a Phase 2 clinical trial evaluating THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.
THR-149 was developed in conjunction with Bicycle Therapeutics PLC (NASDAQ: BCYC)

  • THR-687, is a pan-RGD integrin inhibitor, that is initially being developed as a potential new standard of care for all DME patients. Positive topline results in a Phase 1 clinical study assessing it as a treatment for DME were announced in January 2020. THR-687 is expected to enter a Phase 2 clinical trial by mid-2021. 

THR-687 is an optimized compound derived from a broader library of integrin inhibitors in-licensed from Galapagos NV (Euronext & NASDAQ: GLPG).

Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.

More information is available at

Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.  No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

a d v e r t i s e m e n t